Scholarlink

Background <p>Adverse events (AEs) of S-1 are affected by renal function. A dosage formula for S-1 based on renal function and body surface area (BSA) has been developed, indicating the dose required to achieve a target blood concentration of 5-fluorouracil. This study aimed to explore the usefulness of this formula in adjuvant chemotherapy with S-1 for pancreatic cancer (PC).</p> Methods <p>In the JASPAC-01 trial, the actual initial dose of S-1 was calculated based on the BSA. Patients were divided into three groups by comparing the actual initial S-1 dose with the dose recommended by the S-1 dosage formula: underdose (UD), equal dose (ED), and overdose (OD). The recurrence rate, prognosis, and AEs in each group were evaluated.</p> Results <p>Among 187 eligible patients, 27 (14%), 43 (23%), and 117 (63%) patients were classified into the UD, ED, and OD groups. The incidence of all-grade and grade ≥ 3 anemia during the all-time periods were significantly higher in the OD group (94.9/18.8%) compared to the ED (93.0/4.7%) and UD (81.5/7.4%) groups (<i>P</i> = 0.04). In the UD/ED/OD groups, the planned adjuvant S-1 therapy for 6 months was completed in 77.8/72.1/70.9% (<i>P</i> = 0.51), whereas dose reduction was required in 0/14.0/22.2% (<i>P</i> = 0.01). The 5-year overall survival was slightly worse in OD group (41.9%) than those in the UD/ED groups (48.1/47.6%).</p> Conclusions <p>In the adjuvant S-1 therapy for PC, AEs and dose reduction were more common in the OD group. The S-1 dosage formula may be useful for reducing AEs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis of the randomized clinical trial (JASPAC-01)

  • 期刊论文

  • 发表日期：

    2026年4月17日

查看全文
  • Kazunaga Ishigaki,
  • Yousuke Nakai,
  • Kousuke Kashiwabara,
  • Mitsuhiro Fujishiro,
  • Naoto Gotohda,
  • Hirochika Toyama,
  • Atsuyuki Maeda,
  • Yasuhiro Shimizu,
  • Atsushi Miyamoto,
  • Amane Takahashi,
  • Soichiro Morinaga,
  • Hiroo Yanagibashi,
  • Takuma Goto,
  • Yasunaru Sakuma,
  • Moriaki Tomikawa,
  • Hitoshi Ojima,
  • Yukiyasu Okamura,
  • Akira Fukutomi,
  • Narikazu Boku,
  • Katsuhiko Uesaka

摘要

Background

Adverse events (AEs) of S-1 are affected by renal function. A dosage formula for S-1 based on renal function and body surface area (BSA) has been developed, indicating the dose required to achieve a target blood concentration of 5-fluorouracil. This study aimed to explore the usefulness of this formula in adjuvant chemotherapy with S-1 for pancreatic cancer (PC).

Methods

In the JASPAC-01 trial, the actual initial dose of S-1 was calculated based on the BSA. Patients were divided into three groups by comparing the actual initial S-1 dose with the dose recommended by the S-1 dosage formula: underdose (UD), equal dose (ED), and overdose (OD). The recurrence rate, prognosis, and AEs in each group were evaluated.

Results

Among 187 eligible patients, 27 (14%), 43 (23%), and 117 (63%) patients were classified into the UD, ED, and OD groups. The incidence of all-grade and grade ≥ 3 anemia during the all-time periods were significantly higher in the OD group (94.9/18.8%) compared to the ED (93.0/4.7%) and UD (81.5/7.4%) groups (P = 0.04). In the UD/ED/OD groups, the planned adjuvant S-1 therapy for 6 months was completed in 77.8/72.1/70.9% (P = 0.51), whereas dose reduction was required in 0/14.0/22.2% (P = 0.01). The 5-year overall survival was slightly worse in OD group (41.9%) than those in the UD/ED groups (48.1/47.6%).

Conclusions

In the adjuvant S-1 therapy for PC, AEs and dose reduction were more common in the OD group. The S-1 dosage formula may be useful for reducing AEs.